

Supplemental Digital Content 2. Twelve-month outcomes and p-values comparing subgroups based on predominant activity status during the maintenance phase. Significant p-values are highlighted in bold.

	Inactive	A-NSRFL	A-SRFL	P-value
Eyes	246	199	176	
Patients	229	185	167	
Baseline VA, mean (SD)	60.6 (18.1)	56.3 (21.6)	59.4 (19.7)	0.120
Final VA, mean (SD) ^a	67.4 (16.2)	60.1 (21.1)	66.6 (16.5)	<0.001^d
Unadjusted VA change, mean (95% CI) ^a	6.8 (5, 8.6)	3.8 (1, 6.5)	7.2 (5, 9.4)	0.072
Adjusted VA change, mean (95% CI) ^b	8.2 (6.5, 10.0)	3.3 (1.3, 5.2)	8.2 (6.2, 10.1)	<0.001
VA ≤ 35 letters, % baseline / final ^a	11.8% / 7.7%	17.1% / 12.6%	13.1% / 5.7%	0.048^e
VA ≥ 70 letters, % baseline / final ^a	39.4% / 62.2%	33.2% / 47.7%	40.9% / 56.2%	0.009^f
Injections, median (Q1, Q3) ^c	8 (7, 10)	7 (6, 9)	8 (7, 11)	0.011^g
Visits, median (Q1, Q3) ^c	8 (7, 10)	8 (8, 10)	9 (8, 12)	<0.001^h

^a Last-observation-carried-forward used for non-completers

^b P-value and adjusted VA change based on longitudinal generalised additive models

^c Twelve-month completers only

Pairwise comparisons with Holm-Bonferroni adjustment for multiple comparisons

^d Inactive vs. A-NSRFL ($P < 0.001$); Inactive vs. A-SRFL ($P = 0.669$); A-NSRFL vs. A-SRFL ($P = 0.001$)

^e Inactive vs. A-NSRFL ($P = 0.247$); Inactive vs. A-SRFL ($P = 0.534$); A-NSRFL vs. A-SRFL ($P = 0.105$)

^f Inactive vs. A-NSRFL ($P = 0.009$); Inactive vs. A-SRFL ($P = 0.260$); A-NSRFL vs. A-SRFL ($P = 0.246$)

^g Inactive vs. A-NSRFL ($P = 0.200$); Inactive vs. A-SRFL ($P = 0.007$); A-NSRFL vs. A-SRFL ($P = 0.427$)

^h Inactive vs. A-NSRFL ($P < 0.001$); Inactive vs. A-SRFL ($P < 0.001$); A-NSRFL vs. A-SRFL ($P = 0.998$)